2026-08-21 · 2026-08 / week-3
CoreCivic Prices the Facility Sale Before the Cash-and-Buyback Test
CoreCivic Prices the Facility Sale Before the Cash-and-Buyback Test
Summary: CoreCivic converted four facility sales into approximately $1.1 billion of net proceeds, repaid the outstanding revolver and an incremental term loan, and signed a $500 million accelerated share repurchase. The stock still trades below the ASR's initial implied delivery price, but that price is not a floor: final settlement can move shares or cash, the company surrendered future facility earnings, and government contracts can terminate for convenience or non-appropriation. The long case is a price and capital-allocation reset. The risk is that the market is correctly discounting contract duration and a smaller post-sale earnings base.
Scope: U.S. market, common-stock long only.
Status: Conditional U.S. common-stock Watchlist long. The evidence is fresh and concrete, but entry remains unverified. The current 10/5 gate is reference-only because market structure, the post-ASR denominator, and contract durability are not fully verified.
Run time: 2026-08-21 01:16 Asia/Singapore. Latest market snapshot: regular session, 2026-08-20 17:05:31Z.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CoreCivic (CXW) | Long | Asset-sale cash and debt reduction are real, while the market still prices the company through a pre-sale earnings frame. | Aug. 5 Q2 results and Aug. 10 ASR release | Next post-sale filing, ASR settlement, contract and occupancy disclosures | Executed ASR is observable issuer demand; live short, borrow, options, and fund-flow data are unavailable | Watchlist. Reference-only base case clears +10%, but entry and downside evidence are incomplete | Large enough for common-stock research; same-session depth and exit quality remain unverified | ICE contract termination, lower occupancy, or a post-sale earnings reset |
| 2 | Woodward (WWD) | Long | Strong aerospace and industrial growth and raised EPS guidance coexist with nine-month FCF of $196M against a $300M-$350M guide and a high valuation. | July 29 Q3 release and current quote | Q4 FY26 cash conversion and FY27 outlook | No direct current flow evidence | Watchlist. Operating evidence is strong, but valuation and FCF timing weaken the adverse case | Liquid large-cap industrial, but the current quote is not a sharp new dislocation | FCF misses the guide while the market keeps the growth multiple |
| 3 | Coty (COTY) | Long | Q4 cash flow and the Gucci exit may support deleveraging, but FY27 is a transition year and leverage remains central. | Aug. 20 Q4 event and July Gucci agreement | FY27 plan, Gucci cash receipt, and debt reduction | No direct current flow evidence | Reject for this run. The price gap is large, but net debt and operating uncertainty make the adverse case open-ended | High volume, low-priced common with substantial gap risk | Guidance withdrawal, weaker beauty demand, and debt |
Selected opportunity: CoreCivic (CXW), conditional U.S. common-stock Watchlist long.
Why this one now: The capital-state change is already partly realized. CoreCivic disclosed the net proceeds, debt repayments, ASR funding, initial share delivery, and revised per-share guide in separate dated releases. That is stronger than a buyback authorization or a promised divestiture. The market still has to decide whether the sale proceeds are a balance-sheet reset or compensation for selling away the earnings base.
What should surprise the reader: The important number is not the $1.1 billion sale headline or the $500 million ASR alone. It is the sequence. CoreCivic paid down debt, then deployed cash into a dealer-mediated repurchase that reduces shares but also reduces interest income. The company can improve per-share value while aggregate adjusted net income and EBITDA decline. This is a denominator and cash-quality trade, not a simple buyback-floor story.
Research query audit: I screened with the mechanism-specific combinations "facility sale net proceeds debt repayment ASR government contracts occupancy cash conversion", "detention asset sale buyback initial share delivery final VWAP settlement contract termination", and "aerospace raised EPS guidance nine-month free cash flow shortfall valuation reset". I scanned the current-week folder and the full repository by ticker, issuer, asset-sale mechanism, ASR state, government-contract exposure, and prior direction before selecting CXW.
Why This Is the Best Opportunity Right Now
CoreCivic's Q2 results provided a hard balance-sheet event. The company said net proceeds from four facility sales were approximately $1.1 billion after estimated taxes and transaction costs. A portion was used to repay all $270 million outstanding on the revolving credit facility and the $100 million incremental term loan. The July 2027 notes were also scheduled for full redemption. CoreCivic Q2 2026 results
The second event is more per-share specific. On Aug. 10, CoreCivic paid $500 million to a financial institution under an ASR and received an initial delivery of approximately 12.4 million shares. The implied initial delivery price is approximately $40.32 per share, above the latest $32.85 reference. The final share count depends on average daily VWAP during the ASR term, less a discount, and settlement can require additional shares, share return, or cash. CoreCivic $500 million ASR
The counterpoint is decisive. CoreCivic sold operating facilities and remains exposed to government contract terms. Its release says contracts with ICE can terminate for non-appropriation or convenience. A lower asset base can produce lower future revenue and EBITDA even as debt and shares decline. The next post-sale filing must prove that the retained platform has better common-equity economics, not just that the transaction produced a large accounting gain.
Why This Can Move More Than 5% Soon
The latest reference is $32.85, up $0.86 or 2.69%, with an intraday range of $31.39 to $33.23 and volume of 478,468 shares. The current price is below the ASR's initial implied delivery price, but that is an observed transaction input, not a price floor. The next post-sale cash, debt, common-share, occupancy, and contract disclosure can force a second valuation step.
The near-term move can come from three clocks: the first 10-Q that shows post-sale cash, debt, retained facility earnings, ASR share count, and the interest-income effect; the ASR's eventual VWAP settlement, scheduled before the end of Q2 2027; and government contract and occupancy updates. The event path is research, not yet an order. I do not have verified current full depth, venue quality, exit liquidity, short interest, borrow, options, dealer-flow, or fund-flow data.
10/5 Asymmetry Gate
The measurement basis is the $32.85 reference price, not a verified executable entry.
- Favorable base move: $32.85 to $39.00, approximately +18.7%.
- Credible adverse move inside the scenario map: $32.85 to $31.25, approximately -4.9%, representing a retest of the current low without a contract break.
- Reference-only probability-weighted price: 0.25 times $44.00 plus 0.50 times $39.00 plus 0.25 times $31.25 equals $38.31.
- Reference-only expected return: approximately +16.6% before costs.
- Reference-only gross reward-to-adverse-risk: approximately 3.8:1.
10/5 status: Watchlist, not Trade-qualified. The price-only map has favorable arithmetic, but the adverse bound is not proven against contract termination, occupancy, post-sale EBITDA, or a thin exit path. A null entry cannot establish an executable 10/5 result.
The Setup
CoreCivic operates correctional and government-services facilities. Q2 2026 revenue was $684.9 million, up 27.3% year over year. Adjusted diluted EPS was $0.38, adjusted EBITDA was $109.4 million, and normalized FFO per share was $0.64. Growth was driven by facility activations, higher occupancy in facilities with ICE contracts, and per diem increases.
The company also sold four facilities. The resulting gain dominates GAAP net income guidance, which is not the right measure for this thesis. Updated adjusted diluted EPS guidance was $1.62 to $1.70 before the ASR and $1.64 to $1.73 after the ASR. Updated adjusted EBITDA guidance after the ASR was $434.5 million to $439.5 million, below the pre-ASR range because cash deployment reduces interest income.
| State | Evidence | What it proves | What it does not prove |
|---|---|---|---|
| Facility sale | Four facilities sold; approximately $1.1B net proceeds disclosed | Cash consideration and a balance-sheet event | Recurring retained earnings |
| Debt repayment | $270M revolver and $100M incremental term loan paid down | Lower debt and financing pressure | A higher retained-asset return |
| ASR funding | $500M paid to a dealer; 12.4M initial shares delivered | Observed issuer demand and initial denominator change | A fair-value floor or final share count |
| ASR settlement | VWAP-based final settlement before Q2 FY27 end | Future denominator or cash reconciliation | Immediate cancellation of every claim |
| Contract base | ICE and other government contracts continue under stated terms | Current operating platform | Permanent funding, occupancy, or renewal |
The Market Price
| Metric | Value | Interpretation |
|---|---|---|
| Latest price | $32.85 | Finance snapshot at 2026-08-20 17:05:31Z, regular session |
| Session change | +$0.86 / +2.69% | Modest rebound after recent asset-sale and capital-return repricing |
| Intraday high / low | $33.23 / $31.39 | Full exit depth is unverified |
| Volume | 478,468 shares | Observable tape, not independent positioning evidence |
| Market capitalization | $3.249B | Provider context; post-ASR denominator is not yet filed |
| ASR payment | $500M | About 15.4% of current provider market cap |
| Initial shares delivered | 12.4M | Initial delivery only; final settlement is VWAP-based |
| Initial implied delivery price | ~$40.32 | Transaction arithmetic, not a price floor |
| Remaining repurchase authorization after ASR | ~$255.8M | Potential future demand, not executed demand |
The market-data reference is the CXW Yahoo Finance quote page and timestamped chart endpoint. The finance snapshot reports no reliable direct evidence for current borrow, options, dealer-flow, fund-flow, or full-depth conditions.
The Mispricing
The market can read the facility sale in two ways.
The first is subtraction. CoreCivic sold assets that generated revenue and operating income. Government contracts can be terminated for convenience or non-appropriation. The retained company may be smaller, more dependent on policy, and less valuable than the headline cash proceeds suggest.
The second is reset. CoreCivic converted facilities into cash, repaid debt, removed the revolver balance, redeemed near-term notes, and then used an ASR to reduce the common denominator. That sequence can improve per-share economics even if total revenue falls. The market should not use the one-time sale gain as recurring earnings, but it should not ignore cash that was actually received and deployed.
The mispricing is the gap between those two readings. The correct question is whether retained cash flow, lower debt, and reduced shares compensate common holders for the earnings sold.
The Positioning
The executed ASR is direct issuer activity and useful positioning evidence. The company paid $500M and received 12.4M shares initially. That is stronger than an unused authorization. It also creates a new risk: the dealer's final VWAP settlement can deliver additional shares to the company or require the company to return shares or pay cash.
Positioning score: 3/5. I did not verify current short interest, borrow fee, recall terms, options open interest, dealer exposure, or fund-flow data. Price and volume are observed market behavior, not proof of a crowded short or forced long.
The Catalyst
| Catalyst | Timing | Required test |
|---|---|---|
| First post-sale 10-Q | Next quarterly filing; exact date not verified | Reconcile sale proceeds, taxes, debt, cash, retained revenue, adjusted EBITDA, interest income, common shares, and ASR accounting |
| ASR settlement | Before the end of Q2 FY27 | Confirm final shares received or returned, cash settlement, discount, and post-settlement denominator |
| Contract and occupancy update | Next quarterly operating disclosure | Separate retained contracts, facility populations, per diem, renewals, termination rights, and Prairie ramp |
| Additional asset-sale discussion | Unscheduled | Do not model a new sale until terms, buyer, consideration, taxes, and use of proceeds are filed |
| Repurchase execution | Ongoing but discretionary | Confirm actual shares retired and cash used; authorization alone is not support |
The cheapest disconfirming sequence is the next cash and share-count bridge, followed by contract and occupancy evidence. The ASR's existence is known. The unresolved question is whether it creates durable per-share value after the facility earnings are gone.
The Payoff
The top case is a partial re-rating toward the ASR's initial implied delivery level and beyond. It requires clean debt repayment, retained operating stability, and a final settlement that reduces the common denominator without a damaging cash reversal.
The base case is a smaller re-rating. The market recognizes lower debt and the ASR but keeps a discount for contract duration and policy exposure. The stock reaches $39 without earning the full transaction reference.
The bottom case is a retest of the current low. The company keeps the capital-structure improvement, but contract concerns or weaker occupancy stop the re-rating. A discontinuous policy or contract shock remains a tail risk beyond the scenario map.
Price Target and Probability Map
| Scenario | Probability | Target / Level | Return / Payoff | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 25% | $44.00 | +33.9% | 3-9 months | Debt repayment is confirmed, retained operations hold, ASR settlement reduces shares, and contract risk stays contained | Medium |
| Base Case | 50% | $39.00 | +18.7% | 3-9 months | Market credits lower debt and the observed ASR but keeps a policy and contract discount | Medium |
| Bottom Case | 25% | $31.25 | -4.9% | 3-9 months | Occupancy or contract data disappoints without a full contract break; stock retests the latest low | Medium |
| Invalidation | n/a | Below $28 with a contract or occupancy break | n/a | Any time | Retained platform loses material government revenue, cash is not available as disclosed, or ASR reverses value through a large cash or share settlement | High |
Probability-weighted expected value: $38.31, or approximately +16.6% from the reference before costs. This is price-only scenario arithmetic, not executable EV.
Current market level and timestamp: $32.85 at 2026-08-20 17:05:31Z
Primary instrument: CXW common stock, unlevered, conditional Watchlist only.
10/5 favorable base move: +18.7% reference-only.
10/5 credible adverse move: -4.9% in the defined bottom case, with uncapped contract and policy tail risk.
10/5 measurement basis: reference-only; entry is null.
10/5 status: Watchlist, not Trade-qualified.
Confidence: Medium.
The Kill Shot
The strongest counterparty says CoreCivic sold productive assets because government-contract economics are unstable, then used the cash to buy shares before proving that the retained platform can replace the sold earnings. The ASR can be accretive to per-share figures and still destroy value if contracts terminate, occupancy falls, or the company paid too much for a shrinking asset base.
The load-bearing assumption is that debt reduction and share-count reduction are worth more to common holders than the lost facility earnings. The next 10-Q can falsify that assumption.
What Could Go Wrong
- ICE or another government counterparty terminates a contract for convenience or non-appropriation.
- Retained-facility occupancy, per diem, or contract renewal economics weaken.
- Facility sale proceeds are lower than estimated after taxes, fees, or working-capital adjustments.
- ASR settlement requires CoreCivic to return shares or pay cash instead of receiving additional shares.
- Interest income lost on the $500M cash deployment reduces aggregate earnings more than the denominator reduction helps per-share results.
- The market applies a lower multiple to a smaller, policy-sensitive company even if adjusted EPS holds.
- A policy headline produces a gap below the modeled bottom and invalidates the price-only map.
- Current spread, depth, venue, borrow, options, fund-flow, and exit-liquidity data remain unverified.
What Would Prove This Wrong
- The next filing shows net proceeds or debt repayments materially below disclosure.
- Retained adjusted EBITDA or AFFO falls below the revised guide because sold facilities were more important than assumed.
- A contract termination, non-appropriation event, or occupancy decline removes the retained cash-flow base.
- ASR settlement data shows no durable denominator reduction or a material cash reversal.
- CoreCivic stops repurchases, increases debt again, or uses the remaining authorization while retained cash conversion weakens.
- Current market structure cannot support a staged common-stock entry after all operating tests pass.
Risk Audit
Strongest counterargument: The sale proceeds are compensation for disposing of cash-generating facilities, and government-contract exposure is a first-order risk rather than a valuation discount.
Most fragile assumption: The retained business can produce stable cash flow after the facility sales while lower debt and fewer shares improve common economics.
What the market may already know: The $1.1B proceeds, $500M ASR, debt repayment, and revised EPS guide were disclosed. The edge is the reconciliation of the post-sale retained business.
Why the trade can lose even if the thesis is directionally right: A correct balance-sheet thesis can still lose if contract risk causes a lower multiple, ASR settlement is unfavorable, or liquidity prevents a disciplined exit.
Protection: Evidence-backed operating and contract checks, current cash/debt/share-count reconciliation, and a staged limit-only common-stock expression after gates pass. A stop order alone is not protection.
Best Trade Strategy
Current stance: Watchlist only. No current entry.
Instrument: Common stock only. No options, leverage, margin, market orders, or price-floor language.
Entry: entry.price = null. Do not convert the $40.32 initial ASR arithmetic into an entry or floor.
Upgrade conditions: Fresh regular-session quote not near the intraday low; verified spread, depth, venue, volume quality, and exit liquidity; the next filing reconciles cash, debt, retained operations, and common shares; and ASR settlement remains accretive without a material cash reversal.
Invalidation: Any contract or occupancy break, material cash or debt mismatch, unfavorable ASR settlement, or evidence that the retained earnings base is structurally lower.
Monitoring: Next 10-Q, contract and population disclosures, cash and debt, ASR settlement, actual repurchase table, common denominator, and policy or appropriations changes.
Sources
| Source | Type | Date / timestamp | Use |
|---|---|---|---|
| CoreCivic Q2 2026 financial results | Company release | Aug. 5, 2026 | Q2 operations, facility sales, proceeds, debt repayment, guidance, contract risks |
| CoreCivic $500M ASR announcement | Company release | Aug. 10, 2026 | Payment, initial share delivery, final settlement, remaining authorization, revised guide |
| CoreCivic July 13 note-redemption 8-K | SEC filing | July 13, 2026 | $250M 2027 notes redemption notice |
| CoreCivic March 31 10-Q | SEC filing | May 7, 2026 | Filed common denominator and pre-sale balance-sheet context |
| CoreCivic SEC filings page | Filing index | Retrieved Aug. 21, 2026 | Q2 filing and post-sale filing inventory |
| CXW Yahoo Finance chart | Market data | 2026-08-20 17:05:31Z | Price, range, and volume context |
| Woodward Q3 FY26 results | Candidate source | July 29, 2026 | Ranked candidate: growth, FCF, and guidance |
| Coty Gucci transition agreement | Candidate source | July 7, 2026 | Ranked candidate: cash consideration and debt-reduction path |
| Walmart Q2 FY27 results event | Excluded candidate source | Aug. 20, 2026 | Prior current-week article already covered the same fresh filing |
Research Quality Scorecard
| Criterion | Score | Evidence note |
|---|---|---|
| Market disagreement | 5 | Real cash, debt, and denominator changes conflict with a pre-sale operating frame. |
| Evidence base | 5 | Q2 and ASR releases, note-redemption filing, and market snapshot are current and primary where available. |
| Positioning and flows | 3 | Executed ASR is direct issuer activity; live short, borrow, options, and fund-flow data are missing. |
| Catalyst path | 5 | Post-sale 10-Q, contract evidence, and ASR settlement create observable tests. |
| Payoff architecture | 4 | Base upside is defined, but contract and policy tails remain material. |
| Invalidation discipline | 5 | Contract, cash, denominator, ASR, and execution invalidations are separately monitorable. |
| Differentiated insight | 4 | The distinction is cash-and-denominator reset versus sold earnings, not a generic buyback floor. |
| Client value | 4 | The note is useful as a wait-state decision tree even without a trade. |
Total: 35 / 40. The research is publishable as a Watchlist, but the score does not override the missing executable entry or the unproven adverse bound.
Bottom Line
CoreCivic has delivered a real capital-structure reset: facility-sale cash repaid debt and funded a $500M ASR. That is stronger than an authorization and more useful than a one-time GAAP gain. It is not a floor. The long becomes attractive only if the next filing proves that retained contract cash flow survives the asset sales and the ASR reduces the common denominator without a damaging settlement reversal. Until then, CXW is a conditional Watchlist, not an executable trade.
AI Illustration Prompt
Create a realistic, high-value, high-end elite, beautiful master editorial illustration for The Mispricing Desk about CoreCivic (CXW) pricing a facility-sale cash reset before the retained contract and ASR test. Show an austere institutional operations room with a polished graphite table. On the left, four government-facility models are being converted into a cash ledger marked "$1.1B NET PROCEEDS"; below it, a debt stack stamped "REVOLVER $270M / TERM LOAN $100M REPAID". On the right, a financial institution's ASR document reads "$500M / 12.4M INITIAL SHARES", with a narrow VWAP settlement gate marked "FINAL SHARES OR CASH". In the background, a quiet government facility corridor fades into a contract calendar labeled "NON-APPROPRIATION / CONVENIENCE", showing the retained operating risk without sensationalism. Use charcoal, deep navy, steel, bone paper, and restrained amber. No generic stock charts, rockets, dollar piles, or promotional prison imagery. The mood is forensic, calm, institutional, and skeptical, like a Bloomberg Markets, Barron's, or The Economist cover. Include a subtle but clear watermark or etched text reading "The Mispricing Desk".